Mourabit Halima, Author at MediaMedic

ISTH Guideline丨Latest ISTH Clinical Practice Guidelines for the Treatment of Hemophilia A and B Published

By Mourabit Halima 2024.08.14

Hemophilia, a rare congenital bleeding disorder, is caused by pathogenic variants in the encoding genes, leading to the complete or partial deficiency of clotting factors VIII (Hemophilia A) or IX (Hemophilia B). Treating hemophilia involves certain complexities, and until now, no evidence-based clinical practice guidelines based on the GRADE methodology have been established to guide treatment. The International Society on Thrombosis and Haemostasis (ISTH) has developed evidence-based clinical practice guidelines aimed at systematically reviewing the relevant evidence to provide a scientific basis for treatment decisions in Hemophilia A and B, thereby supporting healthcare providers in their clinical practice. To this end, ISTH formed a globally representative, multidisciplinary guideline panel that prioritized clinical questions based on their urgency and the importance of outcomes to patients and clinicians.

Dr. Huilai Zhang: Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma

By Mourabit Halima 2024.08.14

Marginal zone lymphoma (MZL), a group of indolent mature B-cell lymphomas, presents a significant challenge in treatment selection due to its high heterogeneity. Despite improvements in survival rates for MZL patients with the advent of new drugs and advancements in clinical diagnostic and therapeutic techniques, developing a balanced management plan that addresses both efficacy and safety across a long disease course and lifetime management remains an urgent issue. At the recent "8th Academic Conference on Hematologic Oncology" organized by the Chinese Society of Clinical Oncology (CSCO), Dr. Huilai Zhang from Tianjin Medical University Cancer Institute & Hospital delivered a compelling presentation titled "Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma." This report offers valuable insights and forward-looking guidance for comprehensively understanding the current state of MZL diagnosis and treatment in China and mastering the latest developments in the field. This article summarizes the key points of Professor Zhang's presentation for our readers.

Dr. Huilai Zhang: Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma

By Mourabit Halima 2024.08.14

Dr. Jian Wu: Enhancing Public Awareness on Hepatitis E Prevention and Advancing Diagnosis and Treatment

By Mourabit Halima 2024.08.14

July 28, 2024, marks the 14th World Hepatitis Day. Despite significant progress in combating viral hepatitis, it remains the most prevalent infectious disease in China. Hepatitis E (HEV) is particularly challenging, as China is a high-endemic region for the virus. To address the need for more standardized in-hospital screening procedures, accurate assessments, and a reduction in disease burden, the Chinese Consortium for the Study of Hepatitis E (CCSHE), in collaboration with the Chinese Physician Association for Infectious Disease and the National Clinical Research Center for Infectious Diseases, has developed the "Expert Consensus on the Process of In-Hospital Screening Management of Viral Hepatitis E in China (2023)" (referred to as the Consensus). During a recent academic exchange on hepatitis E prevention and control, Dr. Jian Wu, from the Affiliated Suzhou Hospital of Nanjing Medical University. Hepatology Digest invited Dr. Jian Wu to share his insights and experiences on hepatitis E prevention, diagnosis, and treatment, aiming to further raise public awareness and encourage proactive measures to curb the spread of the virus.

Dr. Yuemin Nan: Strategies for the Prevention and Treatment of Metabolic Associated Fatty Liver Disease (MAFLD) and Lifestyle Adjustments

By Mourabit Halima 2024.08.13

July 28 is "World Hepatitis Day," and this year's theme in China is "Eliminate Hepatitis: Act Now." While the focus remains on viral hepatitis, the prevention and treatment of Metabolic Associated Fatty Liver Disease (MAFLD) should not be overlooked. In honor of World Hepatitis Day, Hepatology Digest invited Dr. Yuemin Nan from the Hebei Medical University Third Hospital to share valuable insights on MAFLD.

Dr. Jidong Jia: In-Depth Analysis of Hepatitis B and C Prevention Strategies, Building a Strong Defense Against Hepatitis

By Mourabit Halima 2024.08.13

July 28, 2024, marks the 14th World Hepatitis Day. Recently, the National Disease Control and Prevention Administration released a report on the national legal infectious disease situation for May 2024, revealing that viral hepatitis remains the most prevalent category B infectious disease. In light of this, Hepatology Digest interviewed Dr. Jidong Jia from Beijing Friendship Hospital, Capital Medical University, to discuss the transmission routes of hepatitis, prevention measures, and more. Below is the transcript of the interview.

AIDS Exclusive Interview: Latest Advances and Challenges in Long-Acting HIV Prevention Technologies

By Mourabit Halima 2024.08.13

At the AIDS 2024 Conference, Dr. Albert Liu from the University of California, San Francisco, delivered a keynote presentation on the latest developments in long-acting HIV prevention technologies. Following his talk, he participated in an exclusive interview with Infectious Diseases Frontier. Dr. Liu highlighted that the field of HIV prevention is currently undergoing exciting transformations. Long-acting drugs, such as bimonthly injections and monthly vaginal rings, have already been approved, significantly improving prevention outcomes and reducing patient burden. Additionally, other technologies in development, such as long-acting tablets, HIV implants, and broadly neutralizing antibodies, show immense potential. However, cost and accessibility remain key challenges to widespread adoption. Future research must focus on the safety, efficacy, and community implementation strategies of these technologies while also simplifying delivery processes to ensure these innovations benefit a broader population and advance HIV prevention efforts.

Spatially resolved transcriptomics: advances and applications

By Mourabit Halima 2024.08.13

In January 2023, a review by Professor Tao Cheng from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——Blood Science . The title of the study is "Spatially resolved transcriptomics: advances and applications". This review summarizes the interplay between technological innovation and biological discovery continues to push the boundaries of what was previously imaginable, translating our approach to complex biological systems and disease pathology.

World’s First Case! Extremely Rare Blood Type Discovered

By Mourabit Halima 2024.08.13

Recently, the Blood Transfusion Department at The First Hospital of Handan in Hebei Province identified an extremely rare B subtype blood type. This blood type results from a heterozygous mutation in exon 7 of the ABO allele, specifically c.449A>G, making it even rarer than the well-known "Panda Blood" (Rh-negative blood).

Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation presenting as pericardial effusion

By Mourabit Halima 2024.08.12

In the evolving field of hematology and oncology, addressing acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is crucial. A recent study highlighting AML relapse as pericardial effusion marks significant progress in this area. Led by Professor Sizhou Feng from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, this research underscores innovative diagnostic and therapeutic strategies.